SEPARATION AGREEMENTSeparation Agreement • November 6th, 2014 • Codexis Inc • Industrial organic chemicals • California
This Separation Agreement (the “Agreement”) by and between David O’Toole (“Executive”) and Codexis, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts:
PLATFORM TECHNOLOGY TRANSFER, COLLABORATION AND LICENSE AGREEMENT BY AND BETWEEN CODEXIS, INC. AND GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED EFFECTIVE AS OF 10 July 2014Collaboration and License Agreement • November 6th, 2014 • Codexis Inc • Industrial organic chemicals • Delaware
THIS PLATFORM TECHNOLOGY TRANSFER, COLLABORATION AND LICENSE AGREEMENT (together with any exhibits attached hereto, this “Agreement”) is made and entered into as of 10 July 2014 (the “Effective Date”), by and between Codexis, Inc., a Delaware corporation, having a place of business at 200 Penobscot Drive, Redwood City, California 94063, United States of America, (“Codexis”) and GlaxoSmithKline Intellectual Property Development Limited, an English company headquartered at 980 Great West Road, Brentford, Middlesex, TW8 9GS, United Kingdom (“GSK”). Codexis and GSK are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
